PERK activation in esophageal carcinomas: Clinicopathological associations

Pathology Research and Practice

Volumn 208, Issue 7, 2012, Pages 398-404

  Tasioudi, K E ^a   Saetta, A A ^a   Sakellariou, S ^a   Levidou, G ^a   Michalopoulos, N V ^b   Theodorou, D ^b   Patsouris, E ^a   Korkolopoulou, P ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Esophageal carcinomas; Immunohistochemistry; K RAS mutation; MAPK pathway; PERK expression

Indexed keywords

B RAF KINASE; GENOMIC DNA; MITOGEN ACTIVATED PROTEIN KINASE;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CODON; CYTOPLASM; ENZYME ACTIVATION; ESOPHAGUS CARCINOMA; EXON; FEMALE; GENE MUTATION; HIGH RESOLUTION MELTING ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PHENOTYPE; PROTEIN EXPRESSION; PYROSEQUENCING; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; CYTOPLASM; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EIF-2 KINASE; ENZYME ACTIVATION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; LASER CAPTURE MICRODISSECTION; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS P21(RAS); YOUNG ADULT;

EID: 84863834975     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2012.05.009     Document Type: Article

References (34)

1. Altiok S., Mezzadra H., Jagannath S., Tsottles N., Rudek M.A., Abdallah N., Berman D., Forastier A., Gibson M.K. A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer. Int. J. Oncol. 2010, 36:19-27.
2. Arber N., Shapira I., Ratan J., Stern B., Hibshoosh H., Moshkowitz M., Gammon M., Fabian I., Halpern Z. Activation of c-K-RAS mutations in human gastrointestinal tumors. Gastroenterology 2000, 118:1045-1050.
3. Bosetti C., Levi F., Ferlay J., Garavello W., Lucchini F., Bertuccio P., Negri E., La Vecchia C. Trends in oesophageal cancer incidence and mortality in Europe. Int. J. Cancer 2008, 122:1118-1129.
4. Calvo F., Agudo-Ibanez L., Crespo P. The Ras-ERK pathway: understanding site-specific signaling provides hope of new anti-tumor therapies. Bioessays 2010, 32:412-421.
5. El-Habr E.A., Tsiorva P., Theodorou M., Levidou G., Korkolopoulou P., Vretakos G., Petraki L., Michalopoulos N.V., Patsouris E., Saetta A.A. Analysis of PIK3CA and B-RAF gene mutations in human astrocytomas: association with activation of ERK and AKT. Clin. Neuropathol. 2010, 29:239-245.
6. Gockel I., Moehler M., Frerichs K., Drescher D., Trinh T.T., Duenschede F., Borschitz T., Schimanski K., Biesterfeld S., Herzer K., Galle P.R., Lang H., Junginger T., Schimanski C.C. Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer. Oncol. Rep. 2008, 20:845-850.
7. Goranova T.E., Ohue M., Shimoharu Y., Kato K. Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors. Clin. Exp. Metastasis 2011, 28:427-435.
8. Guo M., Liu S., Herman J.G., Zhuang H., Lu F. Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450. Cancer Biol. Ther. 2006, 5:152-155.
9. Hanawa M., Suzuki S., Dobashi Y., Yamane T., Kono K., Enomoto N., Ooi A. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int. J. Cancer 2006, 118:1173-1180.
10. Janmaat M.L., Gallegos-Ruiz M.I., Rodriguez J.A., Meijer G.A., Vervenne W.L., Richel D.J., Van Groeningen C., Giaccone G. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J. Clin. Oncol. 2006, 24:1612-1619.
11. Javle M., Pande A., Iyer R., Yang G., LeVea C., Wilding G., Black J., Nava H., Nwogu C. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response. Am. J. Clin. Oncol. 2008, 31:329-334.
12. Kalinina T., Bockhorn M., Kaifi J.T., Thieltges S., Güngör C., Effenberger K.E., Strelow A., Reichelt U., Sauter G., Pantel K., Izbicki J.R., Yekebas E.F. Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus. Int. J. Cancer 2010, 127:1931-1940.
13. Kaneko K., Kumekawa Y., Makino R., Nozawa H., Hirayama Y., Kogo M., Konishi K., Katagiri A., Kubota Y., Muramoto T., Kushima M., Ohmori T., Oyama T., Kagawa N., Ohtsu A., Imawari M. EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma. Front. Biosci. 2010, 15:65-72.
14. Karlou M., Saetta A.A., Korkolopoulou P., Levidou G., Papanastasiou P., Boltetsou E., Isaiadis D., Pavlopoulos P., Thymara I., Thomas-Tsagli E., Patsouris E. Activation of extracellular regulated kinases (ERK1/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B-RAF gene mutations. Pathology 2009, 41:327-334.
15. Kwak E.L., Jankowski J., Thayler S.P., Lauwers G.Y., Brannigan B.W., Harris P.L., Okimoto R.A., Haserlat S.M., Driscoll D.R., BethMuir D.F., Settleman J., Fuchs C.S., Kulke M.H., Ryan D.P., Clark J.W., Sgroi D.C., Haber D.A., Bell D.W. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin. Cancer Res. 2006, 12:4283-4287.
16. Liu Q.W., Fu J.H., Luo K.J., Yang H.-X., Wang J.-Y., Hu Y., Yang H., Bella E. Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma. Dis. Esophagus 2011, 24:374-380.
17. Lord R.V., O'Grady R., Sheehan C., Field A.F., Ward R.L. K-RAS codon 12 mutations in Barrett's oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction. J. Gastroenterol. Hepatol. 2000, 15:730-736.
18. Lorenzen S., Schuster T., Porschen R., Al-Batran S.-E., Hofheinz R., Thuss-Patience P., Moehler M., Grabowski P., Arnold D., Greten T., Muller L., Rothling N., Pesche C., Langer R., Lordick F. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann. Oncol. 2009, 20:1667-1673.
19. Lyronis I.D., Baritaki S., Bizakis I., Krambovitis E., Spandidos D.A. K-RAS mutation, HPV infection and smoking or alcohol abuse positively correlate with esophageal squamous carcinoma. Pathol. Oncol. Res. 2008, 14:267-273.
20. McKay M.M., Morrison D.K. Integrating signals from RTKs to ERK/MAPK. Oncogene 2007, 26:3113-3121.
21. Melhando Rachel E., Alderson D., Tucker O. The changing face of esophageal cancer. Cancers 2010, 2:1379-1404.
22. Mizumoto Y., Kyo S., Mori N., Sakaguchi J., Ohno S., Maida Y., Hashimoto M., Takakura M., Inoue M. Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis. Cancer Sci. 2007, 98:652-658.
23. Mori R., Ishiguro H., Kimura M., Mitsui A., Sasaki H., Tomoda K., Mori Y., Ogawa R., Katada T., Kawano O., Harada K., Fujii Y., Kuwabara Y. PIK3CA mutation status in Japanese esophageal squamous cell carcinoma. J. Surg. Res. 2008, 145:320-326.
24. Pühringer-Oppermann F.A., Stein H.J., Sarbia M. Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas. Dis. Esophagus 2007, 20:9-11.
25. Rygiel A.M., Milano F., Ten Kate F.J., Schaap A., Wang K.K., Peppelenbosch M.P., Bergman J.J.G.H.M., Krishnadath K.K. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus. Cancer Epidemiol. Biomarkers Prev. 2008, 17:1380-1385.
26. Saetta A., Lazaris A.C., Davaris P.S. Detection of ras oncogene point mutations and simultaneous proliferative fraction estimation in gallbladder cancer. Pathol. Res. Pract. 1996, 192:532-540.
27. Sommerer F., Vieth M., Markwarth A., Rohrich K., Vomschlo S., May A., Ell C., Stolte M., Hengge U.R., Wittekind C., Tannapfel A. Mutations of BRAF and K-RAS2 in the development of Barrett's adenocarcinoma. Oncogene 2004, 23:554-558.
28. Sudo T., Mimori K., Nagahara H., Utsunomiya T., Fujita H., Tanaka Y., Shirouzu K., Inoue H., Mori M. Identification of EGFR mutations in esophageal cancer. Eur. J. Surg. Oncol. 2007, 33:44-48.
29. Sunpaweravong P., Suwiwat S., Sunpaweravong S., Puttawibul P., Mitarnun W. Correlation of epidermal growth factor receptor mutation, immunohistochemistry, and fluorescence in situ hybridization in esophageal squamous cell carcinoma. J. Med. Assoc. Thai. 2009, 92:1136-1142.
30. Sunpaweravong P., Sunpaweravong S., Puttawibul P., Mitarnun W., Zeng C., Barón A.E., Franklin W., Said S., Varella-Garcia M. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 2005, 131:111-119.
31. Sugiura K., Ozawa S., Kitagawa Y., Ueda M., Kitajima M. Co-expression of aFGF and FGFR-1 is predictive of a poor prognosis in patients with esophageal squamous cell carcinoma. Oncol. Rep. 2007, 17:557-564.
32. Yazdi A.S., Ghoreschi K., Sander C.A., Röcken M. Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation. Eur. J. Dermatol. 2010, 20:575-579.
33. Zhang J., Zhi H., Zhou C., Ding F., Luo A., Zhang X., Sun Y., Wang X., Wu M., Liu Z. Up-regulation of fibronectin in oesophageal squamous cell carcinoma is associated with activation of the Erk pathway. J. Pathol. 2005, 207:402-409.
34. Zhang X., Makino T., Muchemwa F.C., Lin T., Wakasugi S., Egawa K., Ihn H. Activation of the extracellular signal-regulated kinases signaling pathway in squamous cell carcinoma of the skin. Biosci. Trends 2007, 1:156-160.